Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 plus Anlotinib as Adjuvant Therapy in HCC
NCT05111366Phase 2Unknown
- Start
- Jan 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of benmelstobart and anlotinib in hepatocellular carcinoma (HCC). Primary endpoint: 1-year Recurrence-free survival rate. Status: unknown.
02
Drugs
benmelstobartanlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05111366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05111366.